Bharat Biotech Co. Wednesday issued and made an official announcement on the latest research that has said the Covishield Serum Institute produces more antibodies than Covaxin. The company said this study was not peer-reviewed.
Amid the Twitter war between Raches Bharat Biotech Ella and Kolkata Researcher Dr. Aswadhesh Kumar Singh over Covaxin versus Covishield, Bharat Biotech said that the company would conduct a phase Wednesday 4 vaccine test to examine the effectiveness of the natural world covaxin. Will publish phase 3 trial data in July, the company said. After that, it will apply to a full license.
Covaxin versus covishield.
While the center said that they could not compare these two vaccines be because they were made differently, the researchers did not stop finding out the answer: which vaccines are better between covaxin and covishield. A pre-print study, which has not been reviewed peer-reviewed, recently claimed that both vaccines showed an excellent immune response after two doses. But the Serum Institute of Covishield India produces more antibodies than Covaxin.
Bharat Biotech versus researchers
Opposing research reporting, Head of Business Development Bharat Biotech Dr. Raches Ella went down to social media and said this study had limitations.
Dr. Aswadhesh Kumar Singh, one of the researchers, pointed out that “the whole country will be vaccinated even without the results of the Prefrint Phase 3 – do not forget to be published”.
The company officially issued a statement on Wednesday against this study. “Recent comparative reports on evaluation of immunogenicity responses on proteins after the protein after the first and second doses of the Indian manufacturing vaccine study have many shortcomings. Journals that state comparative reports say more antibodies are produced by Covishield than Covaxin®. This is not a peer publication The review, also did not succeed statistically and scientifically designed. Design research and behavior reflect ad hoc analysis, rather than the specified hypothesis, “said the company.
Phase 3 data will come out in July.
The company on Wednesday said that data would come out in July. First, the data will be submitted to the central drug standard control organization, followed by the peer-reviewed journal. Then Bharat Biotech will apply for a full license, the company said.
So far, the vaccine’s overall efficacy at 78 percent, and its efficacy of inpatient is 100 percent. The 4th phase trial will also be carried out to ensure that Covaxin meets every strict standard, the company said.
Where each candidate stands at the trial and regulatory approval
Covaxin:Â
Bharat Biotech’s Covaxin, on the contrary, has not served three peer-review phase data. The detailed company was published itself after a brief analysis on April 21 but still awaited complete peer data. Submission of Phase 3 test data is also required to obtain a list of the World Health Organization (EUL).
Pfizer BONONTECH:Â
Pfizer published the phase 3 phase clinical trials results in December 2020 and then accepted who was an emergency use approval in January 2021. The trial was carried out with more than 44,000 participants. Pfizer received the approval of the US FDA on December 12, 2021. And now has the approval to be used in the adolescence of 12 to 15 years.
Moderna:Â
Moderna also published three peer-review phase data in December 2020. The study included 30,351 participants who randomly 1: 1 receive an intramuscular injection or a placebo. Vaccines get FDA approval for emergency use only after the results of phase 3 are published.
Johnson and Johnson:Â
Johnson and Johnson Shot received FDA approval on February 27, 2021. It combines phase 1 and 2 studies for the Covid-19 vaccine. Phase 2 is increasingly split into phases 2A and 2B, which includes several aspects often seen in phase trials 3. Phase 3 trials are complete, and the results are published in December.
Covishield:Â
The interim of the AstraZeneca vaccine from the Phase 3 trial was published in December 2020, while the results after further analysis were released in March 2021. He received emergency use in the future from WHO in February.
